1 time for the whole process, 24 hours to remove the virus! The flu "trump drug" mabaloxavir hit

Influenza is an acute respiratory infectious disease caused by influenza virus, common clinical manifestations are fever, fatigue, body aches and headaches and other symptoms, about 290,000 ~ 650,000 deaths and 3 million ~ 5 million serious patients worldwide every year are closely related
to it 。 At present, the two types of commonly used antiviral drugs are neuraminidase inhibitors (NAIs) and M2 ion channel inhibitors, the current influenza virus has strong resistance to M2 ion channel inhibitors, NAIs antiviral efficacy is relatively mild, more worrying is drug resistance, the epidemic of oseltamivir resistant influenza virus H1N1 in 2008-2009 has had a greater impact
on public health.
Therefore, the clinical treatment and prevention of influenza virus require more new anti-influenza virus drugs and new mechanisms
of action.

Baloxavir marboxil (BXM) is a new anti-influenza virus drug jointly developed by Shionogi and Roche of Japan, which mainly inhibits viral replication
by inhibiting cap-dependent nucleases in influenza viruses 。 "CAP-snatching" is a key link in the influenza virus replication cycle, and there is no similar mechanism and corresponding protease in the host cell, so inhibitors against the "CAP-snatching" endonuclease can selectively block the transcription process of the influenza virus without affecting
the host cell.

Mabaloxavir, as a pioneering anti-influenza drug with a completely new mechanism of action, has significant anti-influenza virus activity and good safety
.
Compared with oseltamivir, mabaloxavir only needs to be taken once, the antiviral effect is faster, the adverse drug reaction is few, and it is not easy to develop potential drug resistance
.

Studies have shown that the mabaloxavir group significantly reduces the duration of influenza symptoms by more than one day, and significantly shortens the duration of fever and the duration
of virus release from the body compared with placebo.
Results from a multicenter, double-blind, randomized, placebo-controlled clinical trial conducted in Japan during the 2018-2019 influenza season showed that in this study, 1.
9% of participants on a single dose of Baloxavir developed laboratory-tested clinical symptoms of influenza, compared with 13.
6%
of participants who used placebo.
As a result, Baloxavir has shown significant efficacy
in preventing influenza after contact with sick family members.

The results of the phase III clinical trial of mabaloxavir show that compared with oseltamivir or placebo, mabaloxavir can accelerate the reduction of influenza symptoms and shorten the cure time, patients only need to take the drug once, within 24 hours can stop shedding, reduce the spread of the virus, and the dose is not affected by
age.
One retrospective study demonstrated that the post-treatment costs of treating influenza patients with a single dose of mabaloxavir are generally lower compared with oseltamivir, especially in high-risk patients
.

Compared with traditional M2 channel inhibitors and NAIs, mabaloxavir has advantages in drug resistance, antiviral activity and patient compliance, providing a new treatment option for influenza patients! In the long run, mabaloxavir can not only be used to treat seasonal influenza, but also as a better treatment option for future influenza global pandemics

References:

1.
Neuberger E, Wallick C, Chawla D, Castro RC.
Baloxavir vs oseltamivir: reduced utilization and costs in influenza.
Am J Manag Care.
2022 Mar 1; 28(3):e88-e95.
doi: 10.
37765/ajmc.
2022.
88786.
PMID: 35404552.

2.
Świerczyńska M, Mirowska-Guzel DM, Pindelska E.
Antiviral Drugs in Influenza.
Int J Environ Res Public Health.
2022 Mar 4; 19(5):3018.
doi: 10.
3390/ijerph19053018.
PMID: 35270708; PMCID: PMC8910682.

3.
LI Shaoqiang,FENG Yufei,SUN Xiuping,HU Xin.
Mechanism of action and clinical evaluation of a new anti-influenza virus treatment drug baloxavir marboxil[J].
China Journal of New Drugs,2020,29(14):1572-1575.
)

4.
SUN Chao,QIAO Huan.
New oral anti-influenza drug: baloxavir marboxil[J].
Chinese Journal of New Drugs and Clinical Studies,2019,38(05):262-267.
DOI:10.
14109/j.
cnki.
xyylc.
2019.
05.
002.